CorMedix Inc (CRMD)
Healthcare
Biotechnology
7.50 $
+0.5%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns CorMedix Inc (CRMD)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 84.8% of the shares are freely tradable; institutional investors hold 55.0%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
55.0%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
7.5%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
84.8%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
18.7%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
79Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Deep Track Capital, LP | 8.00 | 6,274,076 | +19.0 | 03/31/2026 |
| BlackRock Inc | 7.61 | 5,967,575 | +3.3 | 03/31/2026 |
| Vanguard Group Inc | 5.73 | 4,499,010 | +13.1 | 12/31/2025 |
| Vanguard Capital Management, LLC | 3.99 | 3,129,656 | +0.0 | 03/31/2026 |
| State Street Corp | 2.79 | 2,191,843 | +14.1 | 03/31/2026 |
| Royce & Associates, LP | 2.41 | 1,887,532 | +679.9 | 03/31/2026 |
| Geode Capital Management, LLC | 2.32 | 1,816,907 | -5.0 | 03/31/2026 |
| UBS Group AG | 1.96 | 1,538,245 | +141.8 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.84 | 2,227,723 | +0.0 | 04/30/2026 |
| iShares Russell 2000 ETF | 2.29 | 1,794,223 | +0.9 | 05/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.